106 related articles for article (PubMed ID: 3686043)
1. Implications of dose intensity for cancer clinical trials.
Semin Oncol; 1987 Dec; 14(4 Suppl 4):1-44. PubMed ID: 3686043
[No Abstract] [Full Text] [Related]
2. Finding the right dose.
Ratain MJ
Clin Adv Hematol Oncol; 2003 Sep; 1(9):517-8, 531. PubMed ID: 16258442
[No Abstract] [Full Text] [Related]
3. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
[TBL] [Abstract][Full Text] [Related]
4. Clinical cancer chronotherapy trials: a review.
Bjarnason GA
J Infus Chemother; 1995; 5(1):31-7. PubMed ID: 7634175
[TBL] [Abstract][Full Text] [Related]
5. Can a rational design for metronomic chemotherapy dosing be devised?
Maraveyas A; Lam T; Hetherington JW; Greenman J
Br J Cancer; 2005 Apr; 92(8):1588-90. PubMed ID: 15846302
[No Abstract] [Full Text] [Related]
6. Dose selection in phase I studies: why we should always go for the most effective.
Haines IE
J Clin Oncol; 2008 Jul; 26(21):3650-2; author reply 3652-3. PubMed ID: 18640947
[No Abstract] [Full Text] [Related]
7. Dose selection in phase I studies: why we should always go for the top.
Sleijfer S; Wiemer E
J Clin Oncol; 2008 Apr; 26(10):1576-8. PubMed ID: 18332465
[No Abstract] [Full Text] [Related]
8. Several apparent errors surfaced on reading the article in the June 2002 issue of Alternative Medicine Review by Kodama et al. entitled "Can maitake MD-fraction aid cancer patients"?
Black W
Altern Med Rev; 2002 Dec; 7(6):451; author reply 452-4. PubMed ID: 12495370
[No Abstract] [Full Text] [Related]
9. NCCN: High-dose chemotherapy. Applications of high-dose chemotherapy with bone marrow/stem cell support in solid tumors.
Vaughan WP
Cancer Control; 2001; 8(6 Suppl 2):50-2. PubMed ID: 11760558
[No Abstract] [Full Text] [Related]
10. [Metronomic chemotherapy in pediatric oncology: hype or hope?].
André N; Pasquier E; Verschuur A; Sterba J; Gentet JC; Rössler J
Arch Pediatr; 2009 Aug; 16(8):1158-65. PubMed ID: 19446445
[TBL] [Abstract][Full Text] [Related]
11. Mobilization of peripheral blood progenitor cells by hematopoietic growth factors.
Chao NJ
Can J Oncol; 1995 Dec; 5 Suppl 1():43-6. PubMed ID: 8853524
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetically guided dose-escalation (PGDE) strategy].
Saeki T
Gan To Kagaku Ryoho; 2000 Jul; 27(7):1069-74. PubMed ID: 10925698
[TBL] [Abstract][Full Text] [Related]
13. [High-dose chemotherapy for breast cancer: are we at the end or at the end of the beginning?].
Lopez M
Clin Ter; 1999; 150(4):259-62. PubMed ID: 10605161
[No Abstract] [Full Text] [Related]
14. Chemotherapy dose intensity facilitated by use of lenograstim--implications for quality of life and survival.
Gisselbrecht C
Eur J Cancer; 1994; 30A Suppl 3():S30-3. PubMed ID: 7535070
[TBL] [Abstract][Full Text] [Related]
15. Risks and benefits of phase 1 oncology trials, revisited.
Kurzrock R; Benjamin RS
N Engl J Med; 2005 Mar; 352(9):930-2. PubMed ID: 15745986
[No Abstract] [Full Text] [Related]
16. "Therapeutic intent" in phase 1 oncology trials: a justifiable objective.
Markman M
Arch Intern Med; 2006 Jul; 166(14):1446-8. PubMed ID: 16864753
[No Abstract] [Full Text] [Related]
17. The clinical application of drug dosing schedules in cancer therapy--Part II.
Reich SD
Cancer Nurs; 1984 Feb; 7(1):59-61. PubMed ID: 6559098
[No Abstract] [Full Text] [Related]
18. The importance of dose intensity in the outcome of chemotherapy.
Hryniuk WM
Important Adv Oncol; 1988; ():121-41. PubMed ID: 3042601
[No Abstract] [Full Text] [Related]
19. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
20. [Clinical phase I studies in oncology and hematology. Concepts, implementation and ethical considerations].
Hanauske AR
Med Klin (Munich); 1996 Apr; 91 Suppl 3():68-70. PubMed ID: 8692122
[No Abstract] [Full Text] [Related]
[Next] [New Search]
